October 1, 2020

COVID-19 Pandemic Delays Treatment for HCC, Says French Cancer Center Analysis

October 08, 2020

Clinical Articles

In patients with advanced hepatocellular carcinoma treated in 2020, there was an observed decrease in planned treatment as well as significant delays noted as a result of the coronavirus disease 2019 pandemic, according to the results of a study of 6 academic referral centers.

Targeted Treatments, Cell Therapies Are Explored in Double-Hit Lymphoma

October 10, 2020

Clinical Articles

The most recent updated World Health Organization classification of lymphoid neoplasms included a new category of mature B-cell neoplasms, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations.

Special Considerations Accompany Newer Agents in R/R B-Cell ALL

October 12, 2020

Clinical Articles

In the past 5 years, 3 new options have emerged to treat patients with relapsed/ refractory acute lymphoblastic leukemia, providing hope for patients with this disease but also raising clinical questions.

Emerging Therapies in CML Undergo Investigation in Chronic-Phase Illness

October 07, 2020

Today’s patients diagnosed with chronic myeloid leukemia can look forward to a near-normal life expectancy, provided they have good access to treatment and monitoring and are properly managed, said Jorge Cortes, MD.

New Therapies in Development for Myelofibrosis

October 15, 2020

Clinical Articles

Building on the transformative impetus from the first FDA-approved JAK 1/2 inhibitor, ruxolitinib, in the clinical landscape of myeloproliferative neoplasms, we are entering a new era of multiple JAK inhibitors and other diverse classes of drugs in rapid clinical development.

Targeted Agents Induce Significant Efficacy in Older, Frail Patients With ALL

October 17, 2020

Clinical Articles

On the treatment of adult patients with acute lymphoblastic leukemia, long-term cure rates in elderly populations, or those older than 55 to 60 years of age, are approximately 15% to 20% and represent a clinically unmet need in this hematologic cancer.

Neoadjuvant Nivolumab Plus Electroporation With Curative Intent Safe and Possible in HCC

October 06, 2020

Clinical Articles

Neoadjuvant immunotherapy with nivolumab plus percutaneous electroporation has demonstrated early signals of promise in the treatment of patients with Barcelona Clinic Liver Cancer class A hepatocellular carcinoma, according to preliminary reports from the phase 2 NIVOLEP trial.

The Battle for the Front Line in CLL Moves Away From Chemoimmunotherapy

October 14, 2020

Clinical Articles

Traditional frontline chemoimmunotherapy regimens used to be the gold standard for treating patients with newly diagnosed chronic lymphocytic leukemia. However, over time, targeted therapies have been inching out the use of chemoimmunotherapy to become the preferred approach in this setting.

SIRT Administered With Nivolumab Demonstrates Positive Safety, Tolerability Results in HCC

October 03, 2020

Clinical Articles

Findings from the NASIR-HCC phase 2 clinical trial demonstrated the safety and tolerability of nivolumab administered with selective internal radiation therapy containing yttrium-90 resin in patients who were ineligible for transarterial chemoembolization.

Patients With Child-Pugh B Benefit From Cabozantinib in HCC

September 30, 2020

Clinical Articles

Better response in survival were observed in patients with Child-Pugh B cirrhosis, a patient population that has limited treatment options, when given cabozantinib in the phase 3 CELESTIAL study.

ILCA Data Reignite Interest in AFP as a Biomarker for HCC

October 04, 2020

Clinical Articles

Although the use of α-fetoprotein has long been established in hepatocellular carcinoma as a biomarker for screening and diagnosis, its role in treatment selection and prognosis following systemic therapy is a moving target.

Lessons From Clinical Trial Setbacks Lead to Next Phase of Oncologic Advances

October 04, 2020

In the wake of the enthusiasm around cancer immunotherapy trial results—with several positive trials presented annually at each American Society of Clinical Oncology meeting in more and more diseases over several years—setbacks have served as a grim reminder that our work is not finished.